Hot melt TTS for administering rotigotine
First Claim
Patent Images
1. A transdermal therapeutic system comprising a drug-containing adhesive matrix, wherein the drug-containing adhesive matrix comprises:
- a solidified melt comprising rotigotine free-base present in an amount of 1-40 weight % with a purity level above 98% anda hot-melt adhesive present in an amount of 50-99 weight % ,wherein the drug-containing adhesive matrix exhibits at 160°
C. a dynamic viscosity of not more than 100 Pa·
s andwherein the drug-containing adhesive matrix is produced by metering the rotigotine free-base into a solvent-free melt at a temperature of between 70°
C. and 200°
C.
3 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to a transdermal therapeutic system (TTS) which contains a rotigotine-containing adhesive layer and is characterized by the fact that the adhesive layer contains a hot-meltable contact adhesive. The invention also relates to the use of rotigotine for producing the adhesive layer of a TTS in a hot melt method, and a method for producing such a TTS.
-
Citations
22 Claims
-
1. A transdermal therapeutic system comprising a drug-containing adhesive matrix, wherein the drug-containing adhesive matrix comprises:
-
a solidified melt comprising rotigotine free-base present in an amount of 1-40 weight % with a purity level above 98% and a hot-melt adhesive present in an amount of 50-99 weight % , wherein the drug-containing adhesive matrix exhibits at 160°
C. a dynamic viscosity of not more than 100 Pa·
s andwherein the drug-containing adhesive matrix is produced by metering the rotigotine free-base into a solvent-free melt at a temperature of between 70°
C. and 200°
C. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
-
Specification